Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive

On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising results of the company’s proprietary BMB-101 drug to treat a rare form of epilepsy, Dravet Syndrome. The chief officer also talks about the firm’s plan to list on the Nasdaq, the common misconceptions on psychedelics, and the overall outlook of the biotech company in the medical space.

Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs.


FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

What Happens If Silver Finally Breaks $50? | Gary Thompson – Silver47

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

On Track To 450K Oz Gold: The Ultimate Growth Story | Oliver Dachsel – Aris Mining

In this interview, Oliver Dachsel, SVP of Capital Markets at Aris Mining Corporation (TSX: ARIS,...

Sunday, February 9, 2025, 12:34:00 PM

Phenomenal Time To Buy GOLD STOCKS! | Adrian Day

In this interview, Adrian Day, President of Adrian Day Asset Management, discusses the disconnect between...

Monday, February 3, 2025, 03:44:00 PM

Hemke: The War On Cash – The Daily Dive

Returning to the Daily Dive to start off the short trading week is Craig Hemke...

Tuesday, February 22, 2022, 01:30:00 PM

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

In this interview, Roger Rosmus, CEO of Goliath Resources (TSXV: GOT), discusses the company's recent...
Tuesday, July 1, 2025, 03:48:00 PM

What’s Going to Push Gold Beyond $2000? — With Mike McGlone

Back on the Daily Dive today is Mike McGlone, a Bloomberg Intelligence senior commodity strategist....

Friday, February 3, 2023, 01:31:05 PM